Meridian Radiopharmaceuticals

Familiar Elements, Novel Fusion

We harness a powerful fusion of biology and physics to fight cancer.

Meridian’s approach links Zoledronic Acid with phosphorous-33, a potent beta-emitting isotope.

We can deliver targeted beta radiation straight to site site of metastases while minimizing harm to healthy tissue.

Development Pipeline

Our pipeline is centered on treating metastatic cancer in the bone one of oncology’s most painful and underserved areas. We are evaluating multiple drug candidates for use across breast, prostate, lung, and other cancers. Our pipeline is centered on treating metastatic cancer in the bone one of oncology’s most painful and underserved areas. We are evaluating multiple drug candidates for use across breast, prostate, lung, and other cancers.

We invite you to connect with Meridian. Whether you’re an investor, a potential partner, or a healthcare advocate, we’re eager to discuss our work and opportunities for collaboration. Reach out to learn how you can be part of our journey to cure bone metastases.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Targeting bone metastases with precision radiotherapy, giving patients new hope where standard treatments fail.

Useful links

Company

Pipeline

Technology

News

730 F Ave - Suite 210
Plano, TX 75074

+1 713 825 8982

Terms & Conditions